Pharmacokinetics of metipranolol in normal man.

Abstract:

:The pharmacokinetic parameters of deacetyl metipranolol were determined after i.v. infusion of increasing doses (6-25mg) in 17 normal volunteers. In a second cross-over trial, deacetyl metipranolol 10 and 20mg were infused in a further 10 subjects, and in a third trial another 20 volunteers received metipranolol 40mg orally. Metipranolol is very rapidly and completely deacetylated in man, so all pharmacokinetic data refer to deacetyl metipranolol, which was assayed by gas chromatography-mass spectrometry. The pharmacokinetic analysis was performed using a recently developed model, using a volume of distribution which is variable with time. The following data were obtained after oral administration: (mean values); lag-time 7.3 min; tmax 50 min, invasion half-life 6.3 min; elimination half-life 3 h; urinary excretion of unchanged drug approximately 4% of the dose. The experiments with infusion of increasing doses, as well as the cross-over study with 10 and 20mg i.v., showed dose-linearity of the kinetics. The respective mean half-lives of elimination were 2.6, 2.9 and 2.8 h. The mean total, renal and extra-renal clearances amounted to 1237 ml/min, 149 ml/min and 1068 ml/min, respectively. The distribution coefficient was 3.5 l/kg, and protein binding amounted to 70% within the range of therapeutic concentrations. Absolute bioavailability was found to be approximately 50% by several different evaluation procedures. Thus, the pharmacokinetic profile of metipranolol shares features of both the lipophilic and the hydrophilic groups of beta-blocking agents.

journal_name

Eur J Clin Pharmacol

authors

Abshagen U,Betzien G,Kaufmann B,Endele G

doi

10.1007/BF00637616

subject

Has Abstract

pub_date

1982-01-01 00:00:00

pages

293-301

issue

4

eissn

0031-6970

issn

1432-1041

journal_volume

21

pub_type

杂志文章
  • Hyperforin in St. John's wort drug interactions.

    abstract::Recently, interactions of herbal medicines with synthetic drugs came into focus of particular interest. In the past 3 years, more than 50 papers were published regarding interactions between St. John's wort (Hypericum perforatum L.; SJW) and prescription drugs. Co-medication with SJW resulted in decreased plasma conce...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00228-006-0096-0

    authors: Madabushi R,Frank B,Drewelow B,Derendorf H,Butterweck V

    更新日期:2006-03-01 00:00:00

  • Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.

    abstract:PURPOSE:Fibroblast growth factor receptor 4 (FGFR4) expression has association with tumor malignancy. In thyroid cancers, FGFR4 has been reported to be characteristically expressed in aggressive thyroid tumors, such as anaplastic thyroid carcinoma (ATC). METHODS:We investigated FGFR4 expression in patients with ATC an...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-020-02842-y

    authors: Yamazaki H,Yokose T,Hayashi H,Iwasaki H,Osanai S,Suganuma N,Nakayama H,Masudo K,Rino Y,Masuda M

    更新日期:2020-05-01 00:00:00

  • Displacement of lidocaine from serum alpha 1-acid glycoprotein binding sites by basic drugs.

    abstract::Since little is known of the number and types of binding sites on alpha 1-acid glycoprotein (AAG) and because drug-drug protein binding interactions often fail to fit a simple model, a study of the effect of 9 known AAG binding drugs on lidocaine free fraction (LFF) was performed. Serum was obtained from 10 healthy ma...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF01037957

    authors: Goolkasian DL,Slaughter RL,Edwards DJ,Lalka D

    更新日期:1983-01-01 00:00:00

  • Allele and genotype frequency of CYP2C9 in Tamilnadu population.

    abstract:OBJECTIVES:To identify the frequency of CYP2C9*1, *2 and *3 alleles and the genotype of CYP2C9 gene in the Tamilian population. METHODS:The study was conducted on 135 unrelated healthy human volunteers. DNA was extracted from the peripheral leukocytes samples and was analyzed using the polymerase chain reaction (PCR)-...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-003-0666-3

    authors: Adithan C,Gerard N,Vasu S,Balakrishnan R,Shashindran CH,Krishnamoorthy R

    更新日期:2003-11-01 00:00:00

  • Pharmacokinetics of meropenem in subjects with renal insufficiency.

    abstract::The pharmacokinetics of IV meropenem (500 mg over 30 min) has been studied in 6 healthy volunteers and 26 patients with various degrees of renal impairment. Blood samples were taken at different times over 24 h in healthy subjects and 36 to 48 h in uraemic patients, and four or five urine samples were collected over 2...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00314864

    authors: Leroy A,Fillastre JP,Etienne I,Borsa-Lebás F,Humbert G

    更新日期:1992-01-01 00:00:00

  • Safety and efficacy of tolcapone in Parkinson's disease: systematic review.

    abstract:PURPOSE:Tolcapone is an efficacious catechol-O-methyltransferase inhibitor for Parkinson's disease (PD). However, safety issues hampered its use in clinical practice. We aimed to provide evidence of safety and efficacy of tolcapone by a systematic literature review to support clinicians' choices in the use of an enlarg...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00228-020-03081-x

    authors: Artusi CA,Sarro L,Imbalzano G,Fabbri M,Lopiano L

    更新日期:2021-01-07 00:00:00

  • A comprehensive review and meta-analysis of risk factors for statin-induced myopathy.

    abstract:PURPOSE:To aid prescribers in assessing a patient's risk for statin-induced myopathy (SIM), we performed a comprehensive review of currently known risk factors and calculated aggregated odds ratios for each risk factor through a meta-analysis. METHODS:This meta-analysis was done through four phases: (1) Identification...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s00228-018-2482-9

    authors: Nguyen KA,Li L,Lu D,Yazdanparast A,Wang L,Kreutz RP,Whipple EC,Schleyer TK

    更新日期:2018-09-01 00:00:00

  • Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.

    abstract:OBJECTIVE:To study the influence of CYP3A4 inhibition by ketoconazole on the disposition of venlafaxine in individuals with different CYP2D6 pheno- and genotypes. METHODS:In an open two-phase study, 21 healthy volunteers with known CYP2D6 pheno- and genotype [14 extensive metabolisers (EMs), 7 poor metabolisers (PMs)]...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00228-003-0627-x

    authors: Lindh JD,Annas A,Meurling L,Dahl ML,AL-Shurbaji A

    更新日期:2003-09-01 00:00:00

  • Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women.

    abstract:PURPOSE:To investigate if the ordinary use of a vaginal suppository containing miconazole results in systemic absorption that is sufficient to affect the activities of CYP1A2 and CYP3A4, which are major drug- and steroid-metabolising enzymes. METHODS:In 20 healthy non-pregnant women aged 18-45 years, the serum concent...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-010-0906-2

    authors: Kjærstad MB,Nielsen F,Nøhr-Jensen L,Zwisler S,Brøsen K,Andersen HR

    更新日期:2010-12-01 00:00:00

  • Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination.

    abstract::Potentiation of the anticoagulant-effect of warfarin by amiodarone was studied in 30 patients. Thirteen received both drugs concurrently, and 17 received warfarin alone and the combination sequentially. Warfarin doses were adjusted to maintain the prothrombin time between 25-30% of control and its kinetics were compar...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00543320

    authors: Almog S,Shafran N,Halkin H,Weiss P,Farfel Z,Martinowitz U,Bank H

    更新日期:1985-01-01 00:00:00

  • Correlation between propranolol in plasma and urine, renin-aldosterone system and blood pressure in essential hypertension.

    abstract::Thirty patients with mild or moderate essential hypertension, and a fixed elevation of diastolic blood pressure, were randomly allocated to three groups and treated with propranolol 40 mg x 4 (Group 1), 80 mg x 4 (group 2) and 160 mg x 4 (Group 3). Blood pressure (BP), pulse rate (PR), plasma renin activity (PRA), pla...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00618774

    authors: Pedersen EB,Kornerup HJ,Pedersen OL,Andreasen F,Bjerregaard P

    更新日期:1981-01-01 00:00:00

  • A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.

    abstract:PURPOSE:The objective of this work was to develop a population pharmacokinetic model for a prolonged-release granule formulation of valproic acid (VPA) in children with epilepsy and to determine the doses providing a VPA trough concentration (Ctrough) within the target range (50-100 mg/L). METHODS:Ninety-eight childre...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-018-2444-2

    authors: Rodrigues C,Chhun S,Chiron C,Dulac O,Rey E,Pons G,Jullien V

    更新日期:2018-06-01 00:00:00

  • The potential of cytokines as safety biomarkers for drug-induced liver injury.

    abstract::Drug-induced liver injury (DILI) is an event that has a detrimental impact on drug development and patient safety; therefore the identification of novel biomarkers that are both sensitive and specific to the liver would have great benefit. Inflammation is known to be associated with human cases of DILI, and given the ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00228-010-0862-x

    authors: Laverty HG,Antoine DJ,Benson C,Chaponda M,Williams D,Kevin Park B

    更新日期:2010-10-01 00:00:00

  • Haemodynamic dose-efficacy of levosimendan in healthy volunteers.

    abstract::Levosimendan is a new calcium-sensitiser intended for the treatment of congestive heart failure. The results of preclinical studies indicate it has positive inotropic and vasodilator effects. In the open study reported here up to 5 mg levosimendan and vehicle were administered to 8 healthy male volunteers at one- to 2...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF02570507

    authors: Lilleberg J,Sundberg S,Häyhä M,Akkila J,Nieminen MS

    更新日期:1994-01-01 00:00:00

  • Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.

    abstract:PURPOSE:Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA class II-IV) and reduced ejection fraction. This study was aimed to evaluate ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00228-016-2062-9

    authors: Langenickel TH,Jordaan P,Petruck J,Kode K,Pal P,Vaidya S,Chandra P,Rajman I

    更新日期:2016-08-01 00:00:00

  • Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder.

    abstract:PURPOSE:Lithium (Li), the first-line treatment of bipolar disorder, was first developed as an immediate-release form with a routine therapeutic drug monitoring 12 h after the last dose. In Europe, the most commonly prescribed form is a sustained release (srLi). Yet no pharmacokinetics (PK) study has been published of s...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-018-2605-3

    authors: Couffignal C,Bertrand J,Sportiche S,Jarroir M,El Balkhi S,Djebrani-Oussedik N,Poupon J,Declèves X,Mentré F,Bellivier F

    更新日期:2019-04-01 00:00:00

  • Acetylator phenotype and congenital malformations.

    abstract::The hypothesis has been tested that an unusual maternal acetylator phenotype can predispose to congenital malformations in the fetus. The acetylator phenotype of normal caucasian control women and of mothers of malformed children was established by measuring urinary sulphadimidine and its acetylated metabolite. A furt...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00609187

    authors: Stoll C,Roth MP,Dott B,Doumit N,Alembik Y,Welsch M,Imbs JL

    更新日期:1989-01-01 00:00:00

  • Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers.

    abstract:INTRODUCTION:Deoxycytidine kinase (DCK) is the rate-limiting enzyme of the intracellular phosphorylation of nucleoside anticancer drugs, including gemcitabine and beta-arabinofuranosylcytosine, to their active triphosphates. This study was performed to assess the occurrence and frequency of DCK polymorphisms in a predo...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-006-0162-7

    authors: Joerger M,Bosch TM,Doodeman VD,Beijnen JH,Smits PH,Schellens JH

    更新日期:2006-08-01 00:00:00

  • Hydralazine-induced lupus: is there a toxic metabolic pathway?

    abstract::The metabolism of hydralazine in a group of slow acetylator patients with the drug-induced lupus syndrome was compared with the metabolism in asymptomatic control subjects. There were no toxicologically significant difference in metabolite excretion between the groups which reached statistical significance, although t...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00556891

    authors: Timbrell JA,Facchini V,Harland SJ,Mansilla-Tinoco R

    更新日期:1984-01-01 00:00:00

  • The pharmacokinetic and pharmacodynamic interactions of ramipril with propranolol.

    abstract::We have studied the pharmacodynamic effects of ramipril, propranolol, and their combination, as well as the effect of propranolol on the pharmacokinetics of ramipril in 12 healthy men (age 24 (SD 6) y, weight 72 (7) kg). Propranolol and placebo, ramipril and placebo, or propranolol and ramipril were given orally for f...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00315392

    authors: van Griensven JM,Seibert-Grafe M,Schoemaker HC,Frölich M,Cohen AF

    更新日期:1993-01-01 00:00:00

  • Single and repeated dose kinetics of the hypnotic agent loprazolam in healthy volunteers.

    abstract::The pharmacokinetics of loprazolam have been studied in eight healthy male volunteers after single and repeated 2 mg oral doses taken at night, for eight nights. The absorption and disposition of unchanged drug (HPLC-GC assay) and receptor active benzodiazepine-type materials (radioreceptor assay) were examined after ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00542354

    authors: Stevens LA,Bevan CD,Salmon J,Krieger J,Perianu M,LeGo A

    更新日期:1983-01-01 00:00:00

  • Dropout rates with olanzapine or risperidone: a multi-centre observational study.

    abstract:OBJECTIVE:In patients with schizophrenia, risperidone and olanzapine are the two most commonly used atypical anti-psychotics. A recent meta-analysis based on randomized trials suggests that, in the long term, olanzapine can have a lower frequency of treatment discontinuation (or dropout) in comparison with risperidone....

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-003-0705-0

    authors: Pelagotti F,Santarlasci B,Vacca F,Trippoli S,Messori A

    更新日期:2004-02-01 00:00:00

  • Methylation of 6-mercaptopurine and 6-thioguanine by thiopurine S-methyltransferase. A comparison of activity in red blood cell samples of 199 blood donors.

    abstract:OBJECTIVES:To compare 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) as substrates for the methylation reaction catalysed by the enzyme thiopurine S-methyltransferase (TPMT). METHODS:TPMT activity in haemolysed red blood cells of healthy blood donors was determined twice, using the same experimental setting and equa...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002280000137

    authors: Kröplin T,Iven H

    更新日期:2000-07-01 00:00:00

  • Antipsychotics and Parkinson's disease: association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment.

    abstract:OBJECTIVE:Psychosis is a common complication of the drug treatment of Parkinson's disease (PD). Treatment of this complication is difficult as most antipsychotic drugs worsen motor symptoms of PD. Only the atypical antipsychotic clozapine improves psychosis without worsening of parkinsonism. The aim of the present stud...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-002-0441-x

    authors: van de Vijver DA,Roos RA,Jansen PA,Porsius AJ,de Boer A

    更新日期:2002-05-01 00:00:00

  • A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome.

    abstract::Ten patients with moderate to severe Raynaud's syndrome were recruited into a four week randomised double blind crossover study to compare the efficacy of UK-38,485 50 mg, a new thromboxane synthetase inhibitor with that of placebo. With the doses used there was no significant difference between the two treatment peri...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Rustin MH,Grimes SM,Kovacs IB,Cooke ED,Bowcock SA,Sowemimo-Coker SO,Turner P,Kirby JD

    更新日期:1984-01-01 00:00:00

  • Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance.

    abstract::Guidelines presented previously for the analysis of plasma concentration versus time data for a drug exhibiting concentration-dependent plasma protein binding were successfully applied to the distributional parameters of a new cephalosporin, ceftriaxone. This approach provided several striking observations when the ph...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF01037956

    authors: McNamara PJ,Gibaldi M,Stoeckel K

    更新日期:1983-01-01 00:00:00

  • The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials.

    abstract:PURPOSE:Although studies have shown the efficacy of laquinimod (LAQ) on disease progression in patients with multiple sclerosis (MS), there is some controversy about whether it improves the types of outcomes and side effects. The main purpose of the present study was to systematically review and meta-analyze the effica...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1007/s00228-019-02827-6

    authors: Rouhi F,Mohammadpour Z,Noureini SK,Abbastabar H,Harirchian MH,Bitarafan S

    更新日期:2020-05-01 00:00:00

  • DHM 32-550 in patients with angina and normal coronary arteries: dose/response relationship.

    abstract::This is the first report of the use of DHM 32-550 a dehydrogenated peptide ergot alkaloid with both alpha and beta adrenoceptor blocking activity, in patients with angina-like chest pain. Five patients were studied to assess a dose/response relationship. No deleterious effects on blood pressure occurred at either rest...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00544034

    authors: Handler CE,Sowton E

    更新日期:1984-01-01 00:00:00

  • Effects of a new diuretic (piretanide) compared with furosemide on renal diluting and concentrating mechanisms in patients with the nephrotic syndrome.

    abstract::The mode and site of action of the new diuretic agent piretanide were investigated in man. The effect of a single oral dose of 12 mg was compared with that of furosemide 80 mg p.o. iin 6 patients with the nephrotic syndrome. Piretanide showed a greater diuretic and natriuretic response than furosemide during maximal w...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00561895

    authors: Marone C,Reubi FC

    更新日期:1980-01-01 00:00:00

  • Procaine hydrolysis defect in uraemia does not appear to be due to carbamylation of plasma esterases.

    abstract::Procaine esterase activity in plasma from patients with renal failure is decreased by 40%. Since cyanate is formed from urea and readily carbamylates certain blood proteins, a possible role for cyanate in the depression of plasma esterase activity in uraemic patients was considered. However, in vitro carbamylation of ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00609899

    authors: Calvo R,Carlos R,Erill S

    更新日期:1983-01-01 00:00:00